# US 6,730,672 B2 · Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,672 B2
- Document ID: US6730672B2
- Status: Granted
- Kind: B2
- Application number: 09/800,745
- Filed: 2001-03-08
- Published: 2002-08-29
- Granted: 2004-05-04
- Earliest claimed: 1994-09-26
- Assignees: Zeneca Limited
- Inventors: Alan Wellington Faull; Andrew Stocker; Colette Marie Mayo; John Preston
- Web page: https://patentgrep.com/patent/US6730672B2

## CPC

- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns compounds of formula (I) wherein each of G1, G2 and G3 is CH or N; m is 1 or 2; R1 includes hydrogen, halogeno and (1-4C)alkyl; M1 is a group of the formula: NR2—L1—T1R3 in which R2 and R3 together form a (1-4C)alkylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2R4)r—L2—T3R5 in which r is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

## Claims

### Claim 1

A compound of the formula I
wherein:
G1 is N and each of G2 and G3 is CH; G1 is CH and each of G2 and G3 is N; or G2 is CH and each of G1 and G3 is N;
m is 1 or 2;
each R1 is independently selected from hydrogen, amino, halogeno, cyano, (1-4C)alkyl and (1-4C)alkoxy;
M1 is a group of the formula
NR2—L1—T1—R3
in which R2 and R3 together form a (1-4C)alkylene group,
L is (1-4C)alkylene, and
T1 is CH or N,
and wherein 1 or 2 methylene groups within L1 and the rings formed when R2 and R3 are linked optionally bear a (1-4C)alkyl substituent;
A is a direct link to the carbonyl group, or A is (1-4C)alkylene;
M2 is a group of the formula
(T2R4)r−L2−T3R5
in which r is 0 or 1,
T2 is N,
T3 is N,
R4 is hydrogen or (1-4C)alkyl,
R5 is hydrogen or (1-4C)alkyl,
or R4 and R5 together form a (1-4C)alkylene, methylenecarbonyl or carbonylmethylene group, or R4 is a (2-3C)alkylene group which is linked to a methylene group within L2 forming a 5- or 6-membered ring involving R4 and T2, or R5 is a (2-3C)alkylene group which is linked to a methylene group within L2 forming a 5- or 6-membered ring involving R5 and T3,
L2 is (1-4C)alkylene or (1-3C)alkylene-carbonyl, and, when r is 1, L2 may also be carbonyl-(1-3 C)alkylene,
and wherein 1 or 2 methylene groups within L2 and the rings formed when R4 and R5, R4 and L2 or R5 and L2 are linked optionally bear a substituent selected from the group consisting of oxo, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, N,N-di-(1-4C)alkylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, piperazin-1-ylcarbonyl, 4-(1-4C)alkylpiperazin-1-ylcarbonyl, N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N-[phenyl-(1-3C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-3C)alkyl]carbamoyl, N-[hydroxy-(2-3 C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[hydroxy-(2-3C)alkyl]carbamoyl, N-[(1-4C)alkoxy-(2-3C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[(1-4C)alkoxy-(2-3C)alkyl]carbamoyl, N-[carboxy-(1-3C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[carboxy-(1-3C)alkyl]carbamoyl, N-[carboxy-(1-3C)alkyl]-N-[hydroxy-(2-3C)alkyl]carbamoyl, N-[carboxy-(1-3C)alkyl]-N-[(1-4C)alkoxy-(2-3 C)alkyl]carbamoyl, N-[(1-4C)alkoxycarbonyl-(1-3C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[(1-4C)alkoxycarbonyl-(1-3C)alkyl]carbamoyl, N-[(1-4C)alkoxycarbonyl-(1-3C)alkyl]-N-[hydroxy-(2-3C)alkyl]carbamoyl, N-[(1-4C)alkoxycarbonyl-(1-3C)alkyl]-N-[(1-4C)alkoxy-(2-3 C)alkyl]carbamoyl, (1-4C)alkyl, carboxy-(1-4C)alkyl, (1-4C)alkoxycarbonyl-(1-4C)alkyl, carbamoyl-(1-4C)alkyl, N-(1-4C)alkylcarbamoyl-(1-4C)alkyl, N,N-di-(1-4C)alkylcarbamoyl-(1-4C)alkyl, pyrrolidin-1-ylcarbonyl-(1-4C)alkyl, piperidinocarbonyl-(1-4C)alkyl, morpholinocarbonyl-(1-4C)alkyl, piperazin-1-ylcarbonyl-(1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-ylcarbonyl-(1-4C)alkyl, N-phenylcarbamoyl-(1-4C)alkyl, N-[phenyl-(1-3 C)alkyl]carbamoyl-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl and phenyl-(1-4C)alkyl,
and wherein any heterocyclic group in said substituent optionally bears 1 or 2 substituents selected from the group consisting of (1-4C)alkyl, (1-4C)alkoxy, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl and N,N-di-(1-4C)alkylcarbamoyl,
and wherein any phenyl or phenylene group in M2 optionally bears 1 or 2 substituents selected from the group consisting of halogeno, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy;
M3 is a direct link to X, or M3 is a group of the formula
L3—(NR6)s
in which s is 0 or 1,
R6 is hydrogen or (1-4C)alkyl, or R5 and R6 together form a (1-4C)alkylene, methylenecarbonyl or carbonylmethylene group, or R6 is a (2-3C)alkylene group which is linked to a methylene group within L3 forming a 5- or 6-membered ring involving NR6,
L3 is (1-4C)alkylene or carbonyl-(1-3C)alkylene, and, when s is 1, L3 may also be (1-3C)alkylene-carbonyl,
and wherein 1 or 2 methylene groups within L3 and the rings formed when R5 and R6 or R6 and L3 are linked optionally bear a substituent selected from the group consisting of oxo, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, N,N-di-(1-4C)alkylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, piperazin-1-ylcarbonyl, 4-(1-4C)alkylpiperazin-1-ylcarbonyl, N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N-[phenyl-(1-3 C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-3C)alkyl]carbamoyl, (1-4C)alkyl, carboxy-(1-4C)alkyl, (1-4C)alkoxycarbonyl-(1-4C)alkyl, carbamoyl-(1-4C)alkyl, N-(1-4C)alkylcarbamoyl-(1-4C)alkyl, N,N-di-(1-4C)alkylcarbamoyl-(1-4C)alkyl, pyrrolidin-1-ylcarbonyl-(1-4C)alkyl, piperidinocarbonyl-(1-4C)alkyl, morpholinocarbonyl-(1-4C)alkyl, piperazin-1-ylcarbonyl-(1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-ylcarbonyl-(1-4C)alkyl, N-phenylcarbamoyl-(1-4C)alkyl, N-[phenyl-(1-3C)alkyl]carbamoyl-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl and phenyl-(1-4C)alkyl,
and wherein any heterocyclic group in said substituent optionally bears 1 or 2 substituents selected from the group consisting of (1-4C)alkyl, (1-4C)alkoxy, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl and N,N-di-(1-4C)alkylcarbamoyl,
and wherein any phenyl or phenylene group in M3 optionally bears 1 or 2 substituents selected from the group consisting of halogeno, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy;
X is oxy, thio, sulphinyl, suiphonyl, sulphonylamino, methylene, (1-4C)alkylmethylene or di-(1-4C)alkylmethylene; and
Q is phenyl, naphthyl, phenyl-(1-4C)alkyl, phenyl-(2-4C)alkenyl, phenyl-(2-4C)alkynyl, (5-7C)cycloalkyl or a heterocyclic moiety containing up to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur, and Q optionally bears 1, 2 or 3 substituents selected from the group consisting of hydroxy, amino, halogeno, cyano, trifluoromethyl, nitro, carboxy, carbamoyl, formyl, formimidoyl, formohydroximoyl, (1-4C)alkoxycarbonyl, (1-4C)alkyl, (1-4C)alkoxy, N-(1-4C)alkylcarbamoyl, N,N-di-(1-4C)alkylcarbamoyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (2-4C)alkanoylamino, (2-4C)alkanoyl, (2-4C)alkanoimidoyl, (2-4C)alkanohydroximoyl, phenyl, heteroaryl, phenoxy, phenylthio, phenylsulphinyl, phenylsulphonyl, heteroaryloxy, heteroarylthio, heteroarylsulphinyl, heteroarylsulphonyl, benzyl and benzoyl,
and wherein said heteroaryl substituent or the heteroaryl group in a heteroaryl-containing substituent comprises a 5- or 6-membered monocyclic heteroaryl ring containing up to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,
and wherein said phenyl, heteroaryl, phenoxy, phenylthio, phenylsulphinyl, phenylsulphonyl, heteroaryloxy, heteroarylthio, heteroarylsulphinyl, heteroarylsulphonyl, benzyl or benzoyl substituent optionally bears 1, 2, 3 or 4 substituents selected from the group consisting of halogeno, trifluoromethyl, cyano, trifluoromethoxy, nitro, (1-4C)alkyl, (1-4C)alkoxy, hydroxy, amino, carboxy, carbamoyl, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-(1-4C)alkylcarbamoyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (2-4C)alkanoylamino and tetrazolyl;
or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of the formula I as claimed in claim 1
wherein
each R1 is independently selected from hydrogen, amino, fluoro, chioro, bromo, cyano, methyl, ethyl and methoxy;
M1 is a group of the formula
NR2—L1—T1R3
in which R2 and R3 together form an ethylene group,
L1 is methylene or ethylene, and
T1 is CH or N,
and wherein 1 or 2 methylene groups within L1 and the ring formed when R2 and R3 are linked optionally bear a substituent selected from the group consisting of methyl and ethyl;
A is a direct link to the carbonyl group or A is methylene;
M2 is a group of the formula
(T2R4)r—L—T3—R5
in which r is 0 or 1,
T2 is N,
T3is N,
R4 is hydrogen, methyl or ethyl,
R5 is hydrogen, methyl or ethyl,
or R4 and R5 together form a methylene, ethylene, trimethylene or methylenecarbonyl group, or R4 is an ethylene group which is linked to a methylene group within L2 forming a 5- or 6-membered ring involving R4 and T2, and
L2 is methylene, ethylene, trimethylene or methylenecarbonyl,
and wherein 1 or 2 methylene groups within L2 and the ring formed when R4 and R5 are linked optionally bear a substituent selected from the group consisting of oxo, carboxy, methoxycarbonyl, ethoxycarbonyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, methyl, ethyl, carboxymethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, hydroxymethyl, methoxymethyl and benzyl,
and wherein the pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, piperazin-1-ylcarbonyl or 4-methylpiperazin-1-ylcarbonyl substituent optionally bears a methyl or ethyl substituent;
M3 is a direct link to X, or M3 is a group of the formula
L3—(NR6)s
in which s is 1,
R6 hydrogen
and L3 is carbonylmethylene or carbonylethylene;
X is thio, sulphinyl, sulphonyl, carbonyl, carbonyloxy or methylene; and
Q is phenyl, naphthyl, benzyl, phenethyl, styryl, 2-phenylethynyl, dibenzofuranyl, biphenylyl, pyridylphenyl or pyridyithienyl, and Q optionally bears 1, 2 or 3 substituents selected from the group consisting of hydroxy, amino, fluoro, chloro, bromo, iodo, cyano, trifluoromethyl, nitro, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, methyl, ethyl, methoxy and ethoxy;
or a pharmaceutically-acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of the formula I as claimed in claim 1
wherein
each R1 is independently selected from hydrogen, amino, chioro, methyl and ethyl;
M1 is a group of the formula
NR2—L1—T1R3
in which R2 and R3 together form an ethylene group,
L1 is ethylene, and
T1 is CH or N;
A is a direct link to the carbonyl group or A is methylene;
M2 is a group of the formula
(T2R4)rL2—T3R5
in which r is 0 or 1,
T2 is N,
T3 is N,
R4 is hydrogen,
R5 is hydrogen,
or R4 and R5 together form an ethylene group, or R4 is an ethylene group which is linked to a methylene group within L2 forming a 5- or 6-membered ring involving R4 and T2, and
L2 is methylene or ethylene,
and wherein 1 or 2 methylene groups within L2 and the ring formed when R4 and R5 are linked optionally bear a substituent selected from the group consisting of carboxy, methoxycarbonyl, ethoxycarbonyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, methyl, ethyl and benzyl,
and wherein the pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, piperazin-1-ylcarbonyl or 4-methylpiperazin-1-ylcarbonyl substituent optionally bears a methyl or ethyl substituent;
M3 is a direct link to X, or M3 is a group of the formula
L3—(NR6)s
in which s is 1,
R6 is hydrogen and
L3 is carbonylmethylene;
X is sulphonyl; and
Q is phenyl, naphthyl, benzyl, phenethyl, styryl, 2-phenylethynyl, dibenzofuranyl, biphenylyl, pyridylphenyl or pyridylthienyl, and Q optionally bears 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, iodo, methyl, ethyl, methoxy and ethoxy;
or a pharmaceutically-acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of the formula I as claimed in claim 1
wherein
m is 1;
R1 is hydrogen;
M1 is a group of the formula
NR2—L1—T1R3
in which R2 and R3 together form an ethylene group,
L1 is methylene or ethylene, and
T1 is CH or N,
and wherein 1 or 2 methylene groups within L1 and the ring formed when R2 and R3 are linked optionally bear a substituent selected from the group consisting of methyl and ethyl;
A is a direct link to the carbonyl group or A is methylene;
M2 is a group of the formula
(T2R4)rL2—T3R5
in which r is 1,
T2 is N,
T3 is N,
R4 is hydrogen, methyl or ethyl,
R5 is hydrogen, methyl or ethyl,
or R4 and R5 together form a methylene, ethylene or trimethylene group, or R4 is an ethylene group which is linked to a methylene group within L2 forming a 5- or 6-membered ring involving R4 and T2, and
L2 is methylene, ethylene or trimethylene,
and wherein 1 or 2 methylene groups within L2 and the ring formed when R4 and R5 are linked optionally bear a substituent selected from the group consisting of oxo, carboxy, methoxycarbonyl, ethoxycarbonyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, methyl, ethyl and benzyl,
and wherein the pyrrolidin-1-ylcarbonyl or piperidinocarbonyl substituent optionally bears 1 or 2 methyl or ethyl substituents;
M3 is a direct link to X, or M3 is a group of the formula
L3—(NR5)s
in which s is 1,
R6 is hydrogen and
L3 is carbonylmethylene or carbonylethylene;
X is suiphonyl; and
Q is 3- or 4-biphenylyl which optionally bears, on the ring attached to X, 1 or 2 substituents selected from the group consisting of hydroxy, fluoro, chloro, bromo, cyano, trifluoromethyl, methyl, ethyl, methoxy and ethoxy and which optionally bears on the terminal phenyl group up to 4 substituents selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, cyano, trifluoromethoxy, methyl, ethyl, methoxy and ethoxy;
or a pharmaceutically-acceptable salt thereof.

### Claim 5 (depends on 1)

A compound of the formula I as claimed in claim 1
wherein
m is 1;
R1 is hydrogen;
M1 is a group of the formula
NR2—L1—T1R3
in which R2 and R3 together form an ethylene group,
L1 is methylene or ethylene, and
T1 is CH or N,
and wherein 1 or 2 methylene groups within L1 and the ring formed when R2 and R3 are linked optionally bear a substituent selected from the group consisting of methyl and ethyl;
A is a direct link to the carbonyl group or A is methylene;
M2 is a group of the formula
(T2R4)r—L2—T3R5
in which r is 1,
T2 is N,
T3is N,
R4 is hydrogen, methyl or ethyl,
R5 is hydrogen, methyl or ethyl,
or R4 and R5 together form a methylene, ethylene or trimethylene group, or R4 is an ethylene group which is linked to a methylene group within L2 forming a 5- or 6-membered ring involving R4 and T2, and
L2 is methylene, ethylene or trimethylene,
and wherein 1 or 2 methylene groups within L2 and the ring formed when R4 and R5 are linked optionally bear a substituent selected from the group consisting of oxo, carboxy, methoxycarbonyl, ethoxycarbonyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, methyl, ethyl and benzyl,
and wherein the pyrrolidin-1-ylcarbonyl or piperidinocarbonyl substituent optionally bears 1 or 2 methyl or ethyl substituents;
M3 is a direct link to X, or M3 is a group of the formula
L3—(NR6)s
in which s is 1,
R6 is hydrogen and
L3 is carbonylmethylene or carbonylethylene;
X is sulphonyl; and
Q is benzyl, phenethyl, styryl or 2-phenylethynyl which optionally bears 1, 2 or 3 substituents selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, methyl, ethyl, methoxy and ethoxy;
or a pharmaceutically-acceptable salt thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound of the formula I as claimed in any one of claims 1 to 5 wherein A is a direct link to the carbonyl group.

### Claim 7 (depends on 1)

A compound of the formula I as claimed in claim 1 wherein M2 is a group of the formula
(T2R4)r—L2—T3R5
in which r is 1,
T2 is N,
T3 is N,
R4 is hydrogen or (1-4C)alkyl,
R5 is hydrogen or (1-4C)alkyl,
or R4 and R5 together form a (1-4C)alkylene group and
L2 is (1-4C)alkylene.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A compound of the formula I as claimed in any one of claims 1 to 5 wherein M3 is a direct link to X.

### Claim 9 (depends on 1, 2)

A compound of the formula I as claimed in claim 1 or claim 2 wherein X is sulphonyl.

### Claim 10 (depends on 1)

A compound of the formula I as claimed in claim 1 wherein Q is phenyl, naphthyl or phenyl-(1-4C)alkyl which optionally bears 1, 2 or 3 substituents selected from the group consisting of hydroxy, halogeno, cyano, trifluoromethyl, (1-4C)alkyl, (1-4C)alkoxy, phenyl, phenoxy, phenylthio, phenylsulphinyl, phenylsulphonyl, benzyl and benzoyl, and wherein the phenyl group in a phenyl-containing substituent optionally bears 1 or 2 substituents selected from the group consisting of halogeno, (1-4C)alkyl and (1-4C)alkoxy.

### Claim 11 (depends on 1)

A compound as claimed in claim 1 of the formula I
wherein G1 is N and each of G2 and G3 is CH; G1 is CH and each of G2 and G3 is N; or G2 is CH and each of G1 and G3 is N;
m is 1;
R1 is hydrogen;
M1 is a group of the formula
NR2-L1-T1R3
in which R2 and R3 together form an ethylene group,
L1 is ethylene, and
T1 is CH or N;
A is a direct link to the carbonyl group;
M2 is a group of formula
(T2R4)r—L2—T3R5
in which r is 1,
T2 is N,
T3 is N,
R4 is hydrogen,
R5 hydrogen,
or R4 and R5 together form an ethylene group, and
L2 is ethylene,
and wherein 1 methylene group within L2 optionally bears a substituent selected from carboxy, ethoxycarbonyl, N-methylcarbamoyl, piperidinocarbonyl, methyl and benzyl;
M3 is a direct link to X, or M3 is a group of the formula
L3—(NR6)s
in which s is 1,
R6 is hydrogen and
L3 is carbonylmethylene;
X is sulphonyl; and
Q is 2-naphthyl which optionally bears 1 or 2 substituents selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, methyl, methoxy and ethoxy;
or a pharmaceutically-acceptable acid-addition salt thereof.

### Claim 12 (depends on 1, 7)

A compound of the formula I as claimed in claim 1 or claim 7 wherein Q is substituted by fluoro, chloro, bromo or iodo.

### Claim 13 (depends on 1, 7)

A compound of the formula I as claim 1 or claim 7 wherein R1 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.

### Claim 14 (depends on 1, 11)

A compound of the formula I as claimed in claim 1 or claim 11 wherein G1 is N, and each of G2 and G3 is CH.

### Claim 15 (depends on 1, 11)

A compound of the formula I as claimed in claim 1 or claim 11 wherein G1 is CH, and each of G2 and G3 is N.

### Claim 16 (depends on 1, 11)

A compound of the formula I as claimed in claim 1 or claim 11 wherein G2 is CH and each of G1 and G3 is N.

### Claim 17

A compound selected from the group consisting of: 1-(6-chloronaphth-2-ylsulphonyl)-4-[1-(4,6-dichloro-1,3,5-triazine-2-yl)piperidin-4-ylcarbonyl]piperazine, 1-(6-chloronaphth-2-ylsulphonyl)-4-[1-(4-pyridazinyl) piperidin-4-ylcarbonyl]piperazine, 1-(2-naphthylsulphonyl)-4-[1-(1,3,5-triazine-2-yl)piperidin-4-ylcarbonyl]piperazine, and pharmaceutically-acceptable salts thereof.

### Claim 18 (depends on 1, 11)

A pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in claim 1 or claim 11, together with a pharmaceutically-acceptable diluent or carrier.

### Claim 19 (depends on 1, 11)

A method of producing an anticoagulant or antithrombotic effect in a warm blooded animal in need thereof, said method comprising administering to said animal an anticoagulant or antithrombotic effective amount of a compound according to claim 1 or claim 11.

### Claim 20 (depends on 1, 11)

A method treating a thrombosis mediated disease or medical condition in a warm blooded animal in need of such treatment, said method comprising administering to said animal an antithrombotic effective amount of a compound according to claim 1 or claim 11.

### Claim 21 (depends on 1, 11)

A method treating a coagulation disorder in a warm blooded animal in need of such treatment, said method comprising administering to said animal an anticoagulation effective amount of a compound according to claim 1 or claim 11.

### Claim 22 (depends on 1, 11)

A method treating a warm blooded animal having a thrombosis or embolism involving Factor Xa mediated coagulation, said method comprising administering to said animal an anticoagulation effective amount of a compound according to claim 1 or claim 11.

### Claim 23 (depends on 1, 11)

A method of producing an anticoagulant effect ex vivo in a biological sample suspected to contain Factor Xa enzyme, said method comprising introducing into said biological sample an anticoagulant-effective amount of a compound according to claim 1 or claim 11.

### Claim 24 (depends on 23)

A method of claim 23 wherein said biological sample is whole blood.

### Claim 25 (depends on 1, 11)

A process for the preparation of an aminoheterocyclic derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in claim 1 or claim 11 which comprises:
(a) for the production of those compounds of the formula I or formula Ia wherein M2 is a group of the formula
(T2R4)r—L2—T3R5
in which T2 is N and r is 1, the reaction of an acid of the formula II, or a reactive derivative thereof,
with an amine of the formula
HNR4—L2—T3R5—M3—X—Q;
(b) for the production of those compounds of the formula I wherein M2 is a, group of the formula
(T2R4)r—L2—T3R5
in which T3 is N, and wherein M3 a direct link to X, the reaction of an amine of formula III
with a compound of the formula Z—X—Q wherein Z is a displaceable group;
(c) for the production of those compounds of the formula I wherein M1 is a group of the formula
NR2—L1—T1R3
in which T1 is N, and wherein A is a direct link to the carbonyl group, the reaction of an amine of the formula IV
with an acid of the formula
HO2C—M2—M3—X—Q
or a reactive derivative thereof;
(d) for the production of those compounds of the formula I wherein M2 is a group of the formula
(T2R4)r—L2—T3R5
in which T3 is N, and wherein M3 is a group of the formula
L3—(NR6)S
in which L3 is carbonylmethylene, the reaction of an amine of the formula III with an acid of the formula
HO2C—CH2—(NR6)S—X—Q
or a reactive derivative thereof;
(e) the reaction of a compound of the formula V
wherein Z is a displaceable group, with an amine of the formula
HNR2—L1—T1R3—A—CO—M2—M3—X—Q
(f) for the production of those compounds of the formula I wherein M2, M3 or Q bears a carboxy or carboxy-containing group, the hydrolysis of a compound of the formula I wherein M2, M3 or Q bears a (1-4C)alkoxycarbonyl group;
(g) for the production of those compounds of the formula I wherein M2, M3 or Q bears a carbamoyl, N-alkylcarbamoyl or N,N-dialkylcarbamoyl group, the reaction of a compound of the formula I wherein M2, M3 or Q bears a carboxy group, or a reactive derivative thereof, with ammonia or an appropriate alkylamine or dialkylamine; or
(h) for the production of those compounds of the formula I wherein Q bears a hydroxy group, the dealkylation of a compound of the formula I wherein Q bears a (1-4C)alkoxy group;
and optionally the reaction of the compound thus obtained with a suitable acid or base using a conventional procedure to form a pharmaceutically-acceptable salt of a compound of the formula I;
and optionally carrying out one of the aforesaid procedures using an optically active starting material, or carrying out a resolution of a racemic form of said compound using a conventional procedure, to obtain an optically active form of a compound of the formula I.
